Alivus Life Sciences Limited (NSE: GLS)

Market Cap	117.44B
Revenue (ttm)	22.05B
Net Income (ttm)	4.24B
Shares Out	122.53M
EPS (ttm)	34.46
PE Ratio	27.81
Forward PE	21.64
Dividend	22.50 (2.26%)
Ex-Dividend Date	n/a

Volume	131,130
Open	994.00
Previous Close	993.90
Day's Range	955.00 - 998.70
52-Week Range	645.35 - 1,335.10
Beta	0.16
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Alivus Life Sciences

Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company’s APIs are used in various therapeutic segments, in...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2011
• Employees: 2,014
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: GLS

Financial Performance

In 2023, Glenmark Life Sciences's revenue was 22.83 billion, an increase of 5.64% compared to the previous year's 21.61 billion. Earnings were 4.71 billion, an increase of 0.84%.